key: cord-0839315-4hek4oyf
authors: Olsen, Sonja J.; Winn, Amber K.; Budd, Alicia P.; Prill, Mila M.; Steel, John; Midgley, Claire M.; Kniss, Krista; Burns, Erin; Rowe, Thomas; Foust, Angela; Jasso, Gabriela; Merced‐Morales, Angiezel; Davis, C. Todd; Jang, Yunho; Jones, Joyce; Daly, Peter; Gubareva, Larisa; Barnes, John; Kondor, Rebecca; Sessions, Wendy; Smith, Catherine; Wentworth, David E.; Garg, Shikha; Havers, Fiona P.; Fry, Alicia M.; Hall, Aron J.; Brammer, Lynnette; Silk, Benjamin J.
title: Changes in influenza and other respiratory virus activity during the COVID‐19 pandemic—United States, 2020–2021
date: 2021-10-08
journal: Am J Transplant
DOI: 10.1111/ajt.16049
sha: 8dba33e4617ecfe4ae20be25896141243d2daef8
doc_id: 839315
cord_uid: 4hek4oyf

nan

The COVID-19 pandemic and subsequent implementation of nonpharmaceutical interventions (e.g., cessation of global travel, mask use, physical distancing, and staying home) reduced the transmission of some viral respiratory pathogens. 1 In the United States, influenza activity decreased in March 2020, was historically low through the summer of 2020, 2 The duration of the effect of the COVID-19 pandemic and associated mitigation measures on respiratory virus circulation is unknown. Circulation of other respiratory viruses might continue to change as pandemic mitigation measures are adjusted and as prevalence of and immunity to both SARS-CoV-2, the virus that causes COVID-19, and immunity to these other viruses waxes and wanes.

In 2020, influenza continued to circulate in the tropics; therefore, resumption of circulation in the United States is possible as global travel resumes. 3 Every year, it is difficult to predict which influenza viruses might circulate during the next season. 4 In the United States, influenza A (H3N2) viruses continue to be identified, but the diversity of the subclades co-circulating was reduced relative to recent RAdV and RV/EV activity continued during 2020 and might be returning to prepandemic circulation patterns. 6, 7 Factors contributing to this distinct circulation are unclear but might include the relative importance of different transmission mechanisms, such as aerosol, droplet, or contact, the role of asymptomatic transmission, and prolonged survival of these nonenveloped viruses on surfaces, all of which might make these viruses less susceptible to nonpharmaceutical interventions, such as mask-wearing and surface cleaning. 8, 9 The delay in circulation of PIVs and HCoVs, which circulate at high levels among children, could be related to some schools suspending in-person classes until late winter. However, the relative absence of HMPV, which affects a similar age group as RSV (i.e., children aged <2 years) is unexplained. The unusual timing of rising RSV detections was also observed in Western Australia. 10 The findings in this report are subject to at least three limitations.

First, changes in health-seeking behaviors during the pandemic (e.g., designated testing sites for COVID-19) might have contributed to a decrease in reported respiratory virus activity if routine health care visits were not made to health care providers who participate in surveillance. Testing for respiratory viruses was somewhat reduced during 2020-2021 but was higher than typically seen during peri- 

* Influenza data as of July 7, 2021. † https://www.cdc.gov/flu/weekl y/overv iew.htm § Some influenza clinical laboratory data and all other respiratory virus data are aggregate, weekly numbers of nucleic acid amplification tests and detections reported to NREVSS, a passive, voluntary surveillance network of clinical, commercial, and public health laboratories. NREVSS aggregate, weekly tests are reported specifically for each pathogen. NREVSS participating laboratories' testing capabilities vary annually, and testing intentions vary for each pathogen. A range of 50-178 laboratories met the pathogen-specific criteria for inclusion criteria during a given surveillance year. https://www.cdc.gov/surve illan ce/nrevs s/index.html ¶ FluSurv-NET and RSV-NET use similar methods; unadjusted cumulative incidence rates are calculated using CDC's National Center for Health Statistics bridged-race postcensal population estimates for the counties included in the surveillance catchment area. Laboratory confirmation is dependent on clinician-ordered testing and cases identified through surveillance are likely an underestimation of the actual number of persons hospitalized with both pathogens.

https://www.cdc.gov/flu/weekl y/influ enza-hospi taliz ation -surve illan ce.htm; https://www.cdc.gov/ncezi d/dpei/eip/eip-netwo rk-activ ities.html ** Genetic characterization was carried out using next-generation sequencing, and the genomic data were analyzed and submitted to public databases (GenBank or EpiFlu). Antigenic characterizations were carried out by hemagglutination inhibition assays or virus neutralizationbased focus reduction assays to evaluate whether genetic changes in circulating viruses affected antigenicity; substantial differences could affect vaccine effectiveness. Testing of seasonal influenza viruses for resistance to the neuraminidase (NA) and polymerase inhibitors was performed at CDC using next-generation sequencing analysis, a functional assay, or both. NA sequences of viruses are examined for the presence of amino acid substitutions previously associated with reduced or highly reduced inhibition by any of the three NA inhibitors 

Acute respiratory illnesses in children in the SARS-CoV-2 pandemic: prospective multicenter study

Decreased influenza activity during the COVID-19 pandemic-United States

Reemergence of influenza virus circulation during 2020 in parts of tropical Asia: implications for other countries. Influenza Other Respir Viruses

Which influenza viruses will emerge following the SARS-CoV-2 pandemic? Influenza Other Respir Viruses

Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices-United States, 2020-21 influenza season

Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand

Trends in viral respiratory infections during COVID-19 pandemic

Respiratory virus shedding in exhaled breath and efficacy of face masks

Sanitizing agents for virus inactivation and disinfection

The interseasonal resurgence of respiratory syncytial virus in Australian children following the reduction of coronavirus disease 2019-related public health measures